US Risks Losing Biotech Race to China Through Price Controls

China is rapidly closing the gap with the United States in biotechnology, initiating clinical trials at rates comparable to American firms. Current US price controls are identified as a primary obstacle preventing American innovation from keeping pace with global competitors. Without policy adjustments, the US risks ceding dominance in a critical sector of the future economy.